Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
BMJ Open|May 15, 2015
Statistical analysis and handling of missing data in cluster randomised trials: protocol for a systematic reviewMallorie Fiero, Shuang Huang, Melanie L Bell
BMC Medical Research Methodology|November 20, 2014
Handling missing data in RCTs; a review of the top medical journalsMelanie L Bell, Mallorie Fiero, Nicholas J Horton, et al.
The American Journal of Medicine|December 17, 2016
High Positive End-Expiratory Pressure Is Associated with Improved Survival in Obese Patients with Acute Respiratory Distress SyndromeChristian Bime, Mallorie Fiero, Zhenqiang Lu, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 16, 2015
Feasibility of Cognitively-Based Compassion Training (CBCT) for breast cancer survivors: a randomized, wait list controlled pilot studySally E Dodds, Thaddeus W W Pace, Melanie L Bell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2025
US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor-Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2-Low or Human Epidermal Growth Factor Receptor 2-Ultralow Breast CancerAsma Dilawari, Hui Zhang, Mirat Shah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2025
US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast CancerSuparna Wedam, Preeti Narayan, Haley Gittleman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2025
US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment SettingJennifer J Gao, Tatiana M Prowell, Haley Gittleman, et al.
Pageof 1